logo
ResearchBunny Logo
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Medicine and Health

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

P. A. Weidenbacher, M. Sanyal, et al.

Introducing DCFHP-alum, a groundbreaking ferritin-based COVID-19 vaccine that shows remarkable promise for global accessibility! Developed by a team of experts including Payton A.-B. Weidenbacher and Prabhu S. Arunchalam from Stanford University, this vaccine generates robust and lasting neutralizing antibodies against various SARS-CoV-2 variants and even SARS-CoV-1. With its impressive stability and potential for high-yield production, it could serve as a yearly booster or primary pediatric vaccine.

00:00
00:00
Playback language: English
Abstract
This paper introduces DCFHP-alum, a ferritin-based COVID-19 vaccine formulated with aluminum hydroxide. The vaccine elicited potent and durable neutralizing antibodies in non-human primates against various SARS-CoV-2 variants, including Omicron, and even SARS-CoV-1. A booster dose given one year after the initial immunization produced a strong anamnestic response. The vaccine's stability at room temperature and potential for high-yield production suggest its suitability for global accessibility and use as a yearly booster or primary pediatric vaccine.
Publisher
Nature Communications
Published On
Apr 17, 2023
Authors
Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogen Tang, Prabhu S. Arunchalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran, Peter S. Kim
Tags
COVID-19 vaccine
aluminum hydroxide
neutralizing antibodies
SARS-CoV-2
vaccine stability
high-yield production
pediatric vaccine

Related Publications

Explore these studies to deepen your understanding of the subject.

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses
Medicine and Health

A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

C. A. Arbeláez, J. Estrada, et al.

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma
Medicine and Health

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma

A. Caputo, F. Nicoli, et al.

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
Medicine and Health

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J. Logue, R. M. Johnson, et al.

COVID-19 vaccine communication and advocacy strategy: a social marketing campaign for increasing COVID-19 vaccine uptake in South Korea
Health and Fitness

COVID-19 vaccine communication and advocacy strategy: a social marketing campaign for increasing COVID-19 vaccine uptake in South Korea

S. Hong

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny